AbbVie's Rinvoq shows superiority over Humira in head-to-head study

Core Insights - AbbVie announced that its newer arthritis drug Rinvoq demonstrated superiority over its previous bestseller Humira in a head-to-head trial, achieving the primary objective of the study [1] Company Summary - Rinvoq is positioned as a successor to Humira, which has been a leading product for AbbVie [1] - The successful trial results may enhance AbbVie's competitive edge in the arthritis treatment market [1]